KindredBio’s manufacturing facilities provide a seamless transfer from
the research and development stage,
to the commercial manufacturing stage.
https://www.kindredbio.com/manufacturing-process/
Our team maintains control over all steps and processes and provides
a unique setting for the development and manufacturing of high-quality, species-specific veterinary biologics.
High standards create dependability when your pet needs it most
The quality of our biologics and pharmaceuticals is just as important
as their development.
KindredBio will manufacture products under the appropriate
regulatory frameworks such as Title 9 and Title 21 of the Code of Federal Regulations for products being licensed through the
USDA and FDA respectively.
KindredBio manufacturing sites in Burlingame, CA and Elwood,
KS follow Current Good Manufacturing Practices (cGMP).
KindredBio acquired, retrofitted, and commissioned an additional manufacturing facility in Elwood, Kansas.
We are uniquely positioned to meet the manufacturing needs of
our promising pipeline with combined facilities reaching
180,000 square feet of full-spectrum production,
from infancy to commercialization,
including labeling and packaging end-to-end processes.
KindredBio Clinical and Commercial Manufacturing can support the production of a broad range of biologics and pharmaceuticals.
This is done through the use of single-use bioreactor
(SUB) up to 2,000L in size and the use of automated vial filling, labeling, and cartoning equipment providing flexibility throughout
the process.
[-chart]www.kindredbio.com/wp-content/uploads/2020/02/burlingame-outside-1.jpg[/chart]
In addition to the Kansas facility, KindredBio commissioned its own dedicated cGMP biologics manufacturing facility in close proximity
to our development labs in Burlingame, California.
The facility utilizes state-of-the-art single-use technology and
has the capacity to meet the requirements for the small scale
clinical and commercial KindredBio biologics supply.
KindredBio is one of the few biopharmaceutical manufacturers that
can capitalize on its production capacity and maintain a steady
revenue stream while ensuring all fulfillment needs are met.
KindredBio provides full service contract development and manufacturing activities,
which are managed by a wholly owned subsidiary, Centaur Biopharmaceutical Services.
Recent KIN News
- Minutes General Meeting • GlobeNewswire Inc. • 05/15/2024 06:00:00 AM
- Procès-Verbal de l’Assemblée générale • GlobeNewswire Inc. • 05/15/2024 06:00:00 AM
- Payment of dividend • GlobeNewswire Inc. • 05/08/2024 12:03:13 PM
- Paiement dividende • GlobeNewswire Inc. • 05/08/2024 12:03:13 PM
- Business update premier trimestre 2024 • GlobeNewswire Inc. • 04/25/2024 05:00:00 AM
- Business update first quarter 2024 • GlobeNewswire Inc. • 04/25/2024 05:00:00 AM
- Publication du rapport annuel 2023 et convocation à l’Assemblée générale • GlobeNewswire Inc. • 04/05/2024 05:59:59 AM
- Publication of annual report 2023 and convening notice for the General Meeting • GlobeNewswire Inc. • 04/05/2024 05:59:59 AM
- Kinepolis achieved record results in 2023 • GlobeNewswire Inc. • 02/22/2024 06:00:00 AM
- Kinepolis a enregistré des résultats records en 2023 • GlobeNewswire Inc. • 02/22/2024 06:00:00 AM
- Update and end of the share buyback program (19 February 2024) • GlobeNewswire Inc. • 02/19/2024 04:45:05 PM
- Mise à jour et fin du programme de rachat d'actions propres (19 février 2024) • GlobeNewswire Inc. • 02/19/2024 04:45:05 PM
- Update share buyback program (12 February 2024) • GlobeNewswire Inc. • 02/12/2024 04:45:07 PM
- Mise à jour concernant le programme de rachat d'actions propres (12 février 2024) • GlobeNewswire Inc. • 02/12/2024 04:45:07 PM
- Mise à jour concernant le programme de rachat d'actions propres (5 février 2024) • GlobeNewswire Inc. • 02/05/2024 04:47:42 PM
- Update share buyback program (5 February 2024) • GlobeNewswire Inc. • 02/05/2024 04:47:42 PM
- Update share buyback program (29 January 2024) • GlobeNewswire Inc. • 01/29/2024 04:45:05 PM
- Mise à jour concernant le programme de rachat d'actions propres (29 janvier 2024) • GlobeNewswire Inc. • 01/29/2024 04:45:05 PM
- Mise à jour concernant le programme de rachat d'actions propres (22 janvier 2024) • GlobeNewswire Inc. • 01/22/2024 04:45:00 PM
- Update share buyback program (22 January 2024) • GlobeNewswire Inc. • 01/22/2024 04:45:00 PM
- Update share buyback program (15 January 2024) • GlobeNewswire Inc. • 01/15/2024 04:45:18 PM
- Mise à jour concernant le programme de rachat d'actions propres (15 janvier 2024) • GlobeNewswire Inc. • 01/15/2024 04:45:18 PM
- Publication of a transparency notification • GlobeNewswire Inc. • 01/11/2024 05:02:45 PM
- Publication relative à une notification de transparence • GlobeNewswire Inc. • 01/11/2024 05:02:45 PM
- Update share buyback program (8 January 2024) • GlobeNewswire Inc. • 01/08/2024 04:45:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM